CytoAurora is a leading biotechnology company that uses advanced technology to contribute to society. With a focus on innovative biomedical technology, CytoAurora analyzes CTC and gene variations to detect and treat cancer in its early stages, ultimately helping doctors improve the survival rate of cancer patients. Their groundbreaking "liquid biopsy" technique, combined with their proprietary "semiconductor biochip" and "A.

I. assisted diagnosis" technologies, not only detects rare target cells in blood but also applies to gene and protein research. CytoAurora specializes in single-cell research and application platforms and possesses its own patents and technologies.

Their single-cell sequencing technology significantly enhances the development of basic and clinical research, providing a vital tool for precise and predictive medicine. With powerful cell technology, CytoAurora conducts safe and non-invasive examinations using minimal human body fluids as samples, analyzing cell characteristics using automated machines and AI interpretation. Their Cell Reveal Series uses proprietary technology to detect subtle cancer markers, enabling early detection and prevention.

CytoAurora continues to be a pioneer in the field of cell technology, exploring, discovering, and inventing with the aim of becoming a legend